Sitagliptin Tablet IP 25 mg: Uses, Benefits, Dosage, Side Effects & Precautions
What is Sitagliptin Tablet IP 25 mg used for?
Sitagliptin Tablet IP 25 mg is an oral prescription medicine used to help control blood glucose levels in adults with type 2 diabetes mellitus. ST GLIPTIN 25, marketed by Steris Healthcare, contains sitagliptin, a DPP-4 inhibitor that helps the body regulate blood sugar in response to meals.
Sitagliptin may be prescribed alone or alongside other diabetes medicines, depending on an individual's blood glucose levels, kidney function, treatment history, and overall diabetes-management plan. It is intended to be used together with a balanced diet, regular physical activity, and appropriate blood-glucose monitoring.
The 25 mg strength is particularly relevant for patients with significantly reduced kidney function, so the prescribed strength should not be changed without medical advice.
Why it's important
Maintaining blood glucose within an appropriate target range is important because persistently elevated blood sugar can contribute to long-term complications affecting the eyes, kidneys, nerves, heart, and blood vessels.
ST GLIPTIN 25 provides a targeted approach to glucose regulation by enhancing the body's natural incretin response. Unlike some diabetes medicines, sitagliptin generally has a low risk of causing hypoglycemia when used alone because its glucose-lowering effect is more dependent on the blood glucose level.
However, the risk of low blood sugar can increase when sitagliptin is combined with insulin or medicines such as sulfonylureas. Regular medical follow-up helps ensure that treatment remains appropriate.
Key Benefits
What are the benefits of Sitagliptin Tablet IP 25 mg?
- Helps improve blood glucose control in adults with type 2 diabetes.
- Supports glucose-dependent insulin release after meals.
- Helps reduce inappropriate glucagon release.
- Generally has a low risk of hypoglycemia when used alone.
- Can be used as part of combination diabetes therapy when clinically appropriate.
- The 25 mg strength can be used in patients with severe renal impairment or end-stage renal disease when prescribed appropriately.
- Can complement dietary management and regular physical activity.
Sitagliptin is not a substitute for insulin in people with type 1 diabetes and should not be used for treatment of diabetic ketoacidosis.
Side Effects
Some people taking ST GLIPTIN 25 may experience mild side effects such as headache, common cold-like symptoms, sore throat, nasal congestion, or gastrointestinal discomfort.
When sitagliptin is combined with insulin or a sulfonylurea, low blood sugar may occur more frequently. Symptoms can include sweating, shaking, hunger, dizziness, weakness, confusion, or rapid heartbeat.
Most people tolerate sitagliptin well when it is used according to medical advice. However, persistent or troublesome symptoms should be discussed with a healthcare professional.
Serious Side Effects
Although uncommon, serious reactions can occur. Acute pancreatitis has been reported with DPP-4 inhibitors. Seek medical attention for persistent severe abdominal pain, particularly if the pain radiates toward the back and is accompanied by vomiting.
Serious allergic reactions, including swelling of the face, lips, tongue, or throat, difficulty breathing, hives, or severe skin reactions, require urgent medical attention.
Sitagliptin has also been associated with severe joint pain in some patients. Report significant or persistent joint pain to your healthcare professional.
Available Substitute
There is no universal substitute for Sitagliptin Tablet IP 25 mg. The appropriate alternative depends on blood glucose control, kidney function, cardiovascular and kidney health, weight-management goals, other medicines, and individual tolerance.
Other DPP-4 inhibitors, such as linagliptin or saxagliptin, may be considered in certain patients, while other diabetes medicines—including metformin, SGLT2 inhibitors, GLP-1 receptor-based therapies, sulfonylureas, or insulin—may be appropriate in different clinical circumstances.
These medicines have different benefits, contraindications, and dosing requirements. Do not replace ST GLIPTIN 25 without consulting your doctor or pharmacist.
Dosage Guidelines
Take ST GLIPTIN 25 exactly as prescribed by your healthcare professional. Sitagliptin is generally taken once daily, with or without food.
The usual dose of sitagliptin for adults with normal kidney function is higher than 25 mg; therefore, 25 mg is generally reserved for patients with severe renal impairment or end-stage renal disease, according to prescribing guidance.
The dose should be selected according to kidney function. Patients with reduced renal function may require periodic assessment of estimated glomerular filtration rate (eGFR).
If you miss a dose, take it when remembered unless it is nearly time for the next dose. Do not take two doses together to compensate.
Precautions & Warnings
ST GLIPTIN 25 is a prescription medicine and should be used under medical supervision.
Tell your healthcare professional if you have:
- Kidney disease or are receiving dialysis
- A previous episode of pancreatitis
- Gallbladder problems
- Heart failure or significant cardiovascular disease
- A history of severe allergic reactions to diabetes medicines
Kidney function is particularly important when determining the correct sitagliptin dose. The 25 mg strength should not be assumed to be the standard dose for all patients.
Inform your doctor about all prescription medicines, over-the-counter products, supplements, and other diabetes medicines you use.
Do not discontinue other prescribed diabetes treatment or insulin without medical advice. Continue recommended dietary, exercise, and blood-glucose-monitoring measures.
How to Use Sitagliptin Tablet IP 25 mg
Take ST GLIPTIN 25 once daily at the time recommended by your healthcare professional. It may generally be taken with or without food. Swallow the tablet with water and follow the prescribed schedule consistently.
Do not increase the dose to obtain faster blood-glucose reduction. Continue regular blood-glucose monitoring as recommended.
If you experience symptoms of hypoglycemia while taking sitagliptin with insulin or a sulfonylurea, follow the hypoglycemia-management instructions provided by your healthcare professional.
Mechanism of Action
Sitagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
After food is consumed, the intestine releases incretin hormones, primarily GLP-1 and GIP. These hormones help stimulate insulin release when blood glucose is elevated and reduce glucagon secretion.
The DPP-4 enzyme normally breaks down these incretin hormones. Sitagliptin inhibits DPP-4, allowing GLP-1 and GIP activity to remain available for longer.
As a result, sitagliptin helps increase glucose-dependent insulin secretion and reduce glucagon release when blood glucose is elevated. This contributes to improved blood glucose control while generally producing less hypoglycemia when used alone compared with medicines that stimulate insulin release independently of glucose levels.
Sitagliptin is primarily eliminated through the kidneys, which is why renal function plays an important role in dose selection.
Conclusion
Sitagliptin Tablet IP 25 mg, marketed as ST GLIPTIN 25 by Steris Healthcare, is a prescription DPP-4 inhibitor used to support blood glucose control in adults with type 2 diabetes. The 25 mg strength is generally intended for patients with significant renal impairment, making appropriate kidney-function assessment important before and during treatment. Sitagliptin works by prolonging the activity of incretin hormones, helping the body increase glucose-dependent insulin release and reduce glucagon secretion. Use ST GLIPTIN 25 exactly as prescribed, maintain recommended diet and physical activity, and seek medical advice for severe abdominal pain, serious allergic symptoms, or persistent side effects.
Comments
Post a Comment